A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

Howard A. Fine, Lyndon Kim, Paul S. Albert, J. Paul Duic, Hilary Ma, Wei Zhang, Tanyifor Tohnya, William D. Figg, Cheryl Royce

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. Experimental Design: A phase I interpatient dose escalation trial of lenalidomide in patients withr ecurrent primary central nervous system tumors was conducted. Results: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m2, with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months. Conclusion: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m2. Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.

Original languageEnglish (US)
Pages (from-to)7101-7106
Number of pages6
JournalClinical Cancer Research
Volume13
Issue number23
DOIs
StatePublished - Dec 1 2007

Fingerprint

Central Nervous System Neoplasms
Glioblastoma
Thalidomide
Angiogenesis Inhibitors
lenalidomide
Hematologic Neoplasms
Brain Neoplasms
Glioma
Anticonvulsants
Biological Availability
Research Design
Pharmacokinetics
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. / Fine, Howard A.; Kim, Lyndon; Albert, Paul S.; Duic, J. Paul; Ma, Hilary; Zhang, Wei; Tohnya, Tanyifor; Figg, William D.; Royce, Cheryl.

In: Clinical Cancer Research, Vol. 13, No. 23, 01.12.2007, p. 7101-7106.

Research output: Contribution to journalArticle

Fine, HA, Kim, L, Albert, PS, Duic, JP, Ma, H, Zhang, W, Tohnya, T, Figg, WD & Royce, C 2007, 'A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors', Clinical Cancer Research, vol. 13, no. 23, pp. 7101-7106. https://doi.org/10.1158/1078-0432.CCR-07-1546
Fine, Howard A. ; Kim, Lyndon ; Albert, Paul S. ; Duic, J. Paul ; Ma, Hilary ; Zhang, Wei ; Tohnya, Tanyifor ; Figg, William D. ; Royce, Cheryl. / A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 23. pp. 7101-7106.
@article{c3c29b00ab6b4da4a2dd798078dc52c0,
title = "A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors",
abstract = "Purpose: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. Experimental Design: A phase I interpatient dose escalation trial of lenalidomide in patients withr ecurrent primary central nervous system tumors was conducted. Results: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m2, with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5{\%} of patients were progression-free at 6 months. Conclusion: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m2. Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.",
author = "Fine, {Howard A.} and Lyndon Kim and Albert, {Paul S.} and Duic, {J. Paul} and Hilary Ma and Wei Zhang and Tanyifor Tohnya and Figg, {William D.} and Cheryl Royce",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1546",
language = "English (US)",
volume = "13",
pages = "7101--7106",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

AU - Fine, Howard A.

AU - Kim, Lyndon

AU - Albert, Paul S.

AU - Duic, J. Paul

AU - Ma, Hilary

AU - Zhang, Wei

AU - Tohnya, Tanyifor

AU - Figg, William D.

AU - Royce, Cheryl

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. Experimental Design: A phase I interpatient dose escalation trial of lenalidomide in patients withr ecurrent primary central nervous system tumors was conducted. Results: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m2, with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months. Conclusion: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m2. Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.

AB - Purpose: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. Experimental Design: A phase I interpatient dose escalation trial of lenalidomide in patients withr ecurrent primary central nervous system tumors was conducted. Results: Thirty-six patients were accrued to the study, of which 28 were evaluable for toxicity, the primary end point of the trial. We show that lenalidomide can be given safely up to doses of 20 mg/m2, with the only toxicity being a probable increased risk of thromboembolic disease. Pharmacokinetic studies reveal good bioavailability, linear kinetics, and no effects of enzyme-inducing antiepileptic drugs on the metabolism of lenalidomide. No objective radiographic responses were seen in any of the treated patients. In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months. Conclusion: Lenalidomide is well tolerated in patients with recurrent glioma in doses up to 20 mg/m2. Treatment may be associated with an increased risk of thromboembolic disease. Preliminary data suggest that single agent activity may be limited in patients with recurrent glioblastoma at the doses evaluated although larger studies will be needed to confirm these observations.

UR - http://www.scopus.com/inward/record.url?scp=37249075870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249075870&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1546

DO - 10.1158/1078-0432.CCR-07-1546

M3 - Article

C2 - 18056189

AN - SCOPUS:37249075870

VL - 13

SP - 7101

EP - 7106

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -